Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

April 2024

Improvements in patient-reported outcomes after treatment with deucravacitinib in patients with psoriatic arthritis: Results from a randomized Phase 2 trial

Arthritis Care Res (Hoboken). 2024 Mar 26 doi: 10.1002/acr.25333 Epub ahead of print

Strand V,

Gossec L,

Coates LC,

Ogdie A,

Choi J,

Zhuo J,

Nowak M,

Deucravacitinib improved physical and social functioning, mental health, fatigue, and pain in a
Phase 2 trial in patients with active PsA. Here, investigators aimed to report the impact of deucravacitinib in a Phase 2 study in patients with active PsA from a patient perspective.

Keywords:

February 2024

Validity and Score Interpretation of the 12-item Psoriatic Arthritis Impact of Disease: An Analysis of Pooled Data from Two Phase 3 Trials of Bimekizumab in Patients with Psoriatic Arthritis

RMD Open 2024;10(1):e003548 doi: 10.1136/rmdopen-2023-003548

Ogdie A,

Ink B,

Taieb V,

Lambert J,

de Wit M

This study reports that the PsAID-12 total score and individual PsAID items capturing disease concepts important to patients with PsA demonstrated robust psychometric properties.

Keywords:

June 2023

Inhibition of Interleukin-17 in Patients with Oligoarticular Psoriatic Arthritis

Rheumatol Ther. 2023;10(4):849-860 doi: 10.1007/s40744-023-00548-y

Ogdie A,

Secukinumab reduced disease activity across a range of outcome measures by week 12, with sustained responses through 52 weeks.